Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TB-TRUST-PLUS: Ultra-Short Regimen for MDR-TB
NCT04717908Phase 3Completed
- Sponsor
- Huashan Hospital
- Start
- Jan 2021
- Primary completion
- Jun 2024
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bedaquiline, linezolid, d-cycloserine, clofazimine, pyrazinamide in multidrug-resistant tuberculosis (MDR-TB), sponsored by Huashan Hospital. Started Jan 2021; status: completed.
02
Drugs
bedaquilinelinezolidd-cycloserineclofaziminepyrazinamide
03
Conditions
multidrug-resistant tuberculosis (MDR-TB)
Beyond the preview
Go deeper on NCT04717908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04717908.